Hemab Therapeutics Prices 16.75M Shares at $18.00
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy COAG?
Hemab Therapeutics priced 16.75M shares at $18.00. The deal size was increased to 16.75M shares from 15.0M and priced at the top end of the $16.00-$18.00 target range. Goldman Sachs, Jefferies and Evercore ISI are acting as joint book running managers for the offering. Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that it says "reimagine the treatment of blood coagulation disorders to sustain life and human resilience."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COAG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COAG
Wall Street analysts forecast COAG stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 18.000
Low
Averages
High
Current: 18.000
Low
Averages
High
No data
About COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hemab Therapeutics Increases IPO Size to $255 Million
- IPO Size Increase: Hemab Therapeutics Holdings has raised its proposed IPO size from 11.8 million shares to 15 million shares, aiming to raise $255 million, which is a 27% increase from previous expectations, indicating strong market interest in its blood coagulation disorder treatments.
- Significant Clinical Progress: The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 trials and is ready to enter Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, showcasing the potential of its product pipeline.
- Clear Market Positioning: Hemab focuses on providing prophylactic subcutaneous treatments for rare coagulation disorders, addressing a significant gap in existing treatment options, which is expected to attract patient populations in need of new therapies and enhance its competitive edge.
- Defined Listing Plans: Hemab plans to list on Nasdaq under the symbol COAG during the week of April 27, 2026, with joint bookrunners including Goldman Sachs, Jefferies, and Evercore ISI, reflecting the professionalism and market confidence in its financing strategy.
See More
Hemab and Seaport Shares Surge on Strong IPO Debuts
- Hemab's Debut Performance: Hemab Therapeutics priced its IPO at $18 per share, opening at $27, reflecting a ~50% increase, and reaching $29.68 by 1:30 PM ET, indicating strong market confidence in its bleeding disorder treatments.
- Seaport's Stock Surge: Seaport Therapeutics also priced its IPO at $18, opening at $21, a ~17% rise, and climbing to $22.51 by 1:30 PM ET, showcasing investor optimism regarding its neuropsychiatric drug development.
- Significant Fundraising: The two companies collectively raised over $550 million through upsized IPOs, with Hemab expecting $301.5 million and Seaport $254.9 million, providing robust funding for future R&D and market expansion.
- Positive Market Reaction: The successful listings of both companies not only highlight the vitality of the biotech sector but also reflect investor confidence in new drug development, particularly driven by positive clinical trial results, potentially attracting more attention to this field.
See More
Hemab and Seaport Price IPOs to Raise Over $550M
- Hemab IPO Details: Hemab Therapeutics priced its IPO at $18.00 per share for 16.75 million shares, raising approximately $301.5 million, indicating strong market demand for its bleeding disorder treatments and solidifying its position in the biotech sector.
- Seaport IPO Pricing: Seaport Therapeutics priced nearly 14.2 million shares at $18.00 each, expecting to raise about $254.9 million, reflecting investor confidence in its neuropsychiatric drug development and providing crucial funding support in a competitive biopharmaceutical market.
- Underwriter Options: Both companies have granted underwriters a 30-day option, with Hemab allowing for an additional 2.5 million shares and Seaport 2.1 million shares, a strategy that not only provides additional funding flexibility but could also enhance fundraising if market demand remains strong.
- Market Response and Timeline: Both firms aim to close their offerings on May 4, and the positive market response to these IPOs may drive overall investment enthusiasm in the biotech sector, attracting more investor attention to emerging biopharmaceutical companies.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
Hemab Therapeutics Raises $302 Million in IPO for Coagulation Disorder Treatments
- Expanded Financing: Hemab Therapeutics successfully raised $302 million by offering 16.8 million shares at $18 each, exceeding its original plan by over 50%, reflecting strong market demand for its blood coagulation disorder treatments.
- Clinical Advancement: The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 trials and is ready to enter Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, indicating its potential in treating rare diseases.
- Diverse R&D Pipeline: Hemab is also advancing HMB-002 in Phase 1/2 trials for Von Willebrand Disease, further enriching its treatment options for coagulation-related disorders and addressing urgent market needs for new therapies.
- Market Positioning and Trading Info: The company will trade on Nasdaq under the symbol COAG, with joint bookrunners including Goldman Sachs, Jefferies, and Evercore ISI, showcasing its strong market positioning and potential for future growth.
See More
Hemab Therapeutics Increases IPO Size to $255 Million
- IPO Size Increase: Hemab Therapeutics Holdings has raised its proposed IPO size from 11.8 million shares to 15 million shares, aiming to raise $255 million, which is a 27% increase from previous expectations, indicating strong market interest in its blood coagulation disorder treatments.
- Significant Clinical Progress: The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 trials and is ready to enter Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, showcasing the potential of its product pipeline.
- Clear Market Positioning: Hemab focuses on providing prophylactic subcutaneous treatments for rare coagulation disorders, addressing a significant gap in existing treatment options, which is expected to attract patient populations in need of new therapies and enhance its competitive edge.
- Defined Listing Plans: Hemab plans to list on Nasdaq under the symbol COAG during the week of April 27, 2026, with joint bookrunners including Goldman Sachs, Jefferies, and Evercore ISI, reflecting the professionalism and market confidence in its financing strategy.
See More
Hemab and Seaport Shares Surge on Strong IPO Debuts
- Hemab's Debut Performance: Hemab Therapeutics priced its IPO at $18 per share, opening at $27, reflecting a ~50% increase, and reaching $29.68 by 1:30 PM ET, indicating strong market confidence in its bleeding disorder treatments.
- Seaport's Stock Surge: Seaport Therapeutics also priced its IPO at $18, opening at $21, a ~17% rise, and climbing to $22.51 by 1:30 PM ET, showcasing investor optimism regarding its neuropsychiatric drug development.
- Significant Fundraising: The two companies collectively raised over $550 million through upsized IPOs, with Hemab expecting $301.5 million and Seaport $254.9 million, providing robust funding for future R&D and market expansion.
- Positive Market Reaction: The successful listings of both companies not only highlight the vitality of the biotech sector but also reflect investor confidence in new drug development, particularly driven by positive clinical trial results, potentially attracting more attention to this field.
See More
Hemab and Seaport Price IPOs to Raise Over $550M
- Hemab IPO Details: Hemab Therapeutics priced its IPO at $18.00 per share for 16.75 million shares, raising approximately $301.5 million, indicating strong market demand for its bleeding disorder treatments and solidifying its position in the biotech sector.
- Seaport IPO Pricing: Seaport Therapeutics priced nearly 14.2 million shares at $18.00 each, expecting to raise about $254.9 million, reflecting investor confidence in its neuropsychiatric drug development and providing crucial funding support in a competitive biopharmaceutical market.
- Underwriter Options: Both companies have granted underwriters a 30-day option, with Hemab allowing for an additional 2.5 million shares and Seaport 2.1 million shares, a strategy that not only provides additional funding flexibility but could also enhance fundraising if market demand remains strong.
- Market Response and Timeline: Both firms aim to close their offerings on May 4, and the positive market response to these IPOs may drive overall investment enthusiasm in the biotech sector, attracting more investor attention to emerging biopharmaceutical companies.
See More
April IPO Market Rebounds with $7.3 Billion Raised
- Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
- Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
- Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
- Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
See More
Hemab Therapeutics Raises $302 Million in IPO for Coagulation Disorder Treatments
- Expanded Financing: Hemab Therapeutics successfully raised $302 million by offering 16.8 million shares at $18 each, exceeding its original plan by over 50%, reflecting strong market demand for its blood coagulation disorder treatments.
- Clinical Advancement: The company's lead candidate, sutacimig (HMB-001), has completed Phase 2 trials and is ready to enter Phase 3 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, indicating its potential in treating rare diseases.
- Diverse R&D Pipeline: Hemab is also advancing HMB-002 in Phase 1/2 trials for Von Willebrand Disease, further enriching its treatment options for coagulation-related disorders and addressing urgent market needs for new therapies.
- Market Positioning and Trading Info: The company will trade on Nasdaq under the symbol COAG, with joint bookrunners including Goldman Sachs, Jefferies, and Evercore ISI, showcasing its strong market positioning and potential for future growth.
See More
